Neurocrine Biosciences (NBIX) news
Recent news
Neurocrine Biosciences, Inc.: BMO cuts target price to $150 from $164
On October 12, 2026, BMO lowered its price target for Neurocrine Biosciences, Inc. (NASDAQ: NBIX) to $150 from $164, reflecting a more cautious outlook on the biotechnology company’s near-term prospects. This adjustment follows a broader trend of analyst revisions, with three major firms reducing…
AInvest Wire · 2d agoNeurocrine Biosciences appoints Eiry W. Roberts, M.D., as chief medical officer
AInvest Wire · Sep 28, 2026Neurocrine Biosciences, Inc.: RBC cuts target price to $187 from $198
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has seen recent analyst activity that reflects evolving expectations for the company’s stock. On May 29, 2026, RBC Capital adjusted its price target for Neurocrine from $180 to $183, while maintaining an Outperform rating . More recently, however, RBC has…
AInvest Wire · Sep 21, 2026Neurocrine Biosciences Inc: Morgan Stanley raises target price to $183.00 from $182.00
AInvest Wire · Sep 11, 2026Neurocrine Biosciences, Inc.: Citigroup raises target price to $253 from $249
AInvest Wire · Sep 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.